![Maureen Deehan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Maureen Deehan currently works at Vivtex Corp., as Chief Executive Officer from 2023.
Dr. Deehan also formerly worked at Nordic Nanovector ASA, as Head-Corporate Development & Strategy.
Dr. Deehan received her undergraduate degree from the University of Strathclyde and doctorate degree from the University of Glasgow School of Medicine.
| Sociétés | Poste | Début |
|---|---|---|
Vivtex Corp.
 Vivtex Corp. Miscellaneous Commercial ServicesCommercial Services Operates as a drug development company that focuses on Gastrointestinal related diseases using oral oligonucleotide therapeutics | Directeur Général | 21/02/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
| THOR MEDICAL | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
University of Strathclyde
 University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Develops innovative anticancer therapeutics | Health Technology |
University of Glasgow School of Medicine
 University of Glasgow School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vivtex Corp.
Vivtex Corp. Miscellaneous Commercial ServicesCommercial Services Operates as a drug development company that focuses on Gastrointestinal related diseases using oral oligonucleotide therapeutics | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
